机会性感染的免疫治疗：现状与未来展望。
Immunotherapy for opportunistic infections: Current status and future perspectives.
作者信息
Fuji Shigeo, Löffler Jürgen, Einsele Hermann, Kapp Markus
机构信息
a Department of Haematopoietic Stem Cell Transplantation , National Cancer Center Hospital , Tokyo , Japan.
b Department of Internal Medicine II , Division of Hematology/Oncology, University Hospital of Würzburg , Würzburg , Germany.
出版信息
Virulence. 2016 Nov 16;7(8):939-949. doi: 10.1080/21505594.2016.1207038. Epub 2016 Jul 6.
Abstract
The outcome after allogeneic haematopoietic stem cell transplantation (allo-HSCT) has significantly improved during the last decades. However, opportunistic infections such as viral and mold infections are still a major obstacle for cure. Within this field, adoptive T cell therapy against pathogens is a promising treatment approach. Recently, the techniques to develop T cell products including pathogen-specific T cells have been sophisticated and are now available in accordance to good manufacturing practice (GMP). Here, we aim to summarize current knowledge about adoptive T cell therapy against viral and mold infections.
摘要
在过去几十年中，异基因造血干细胞移植（allo-HSCT）后的疗效有了显著改善。然而，病毒和霉菌感染等机会性感染仍然是治愈的主要障碍。在这一领域，针对病原体的过继性T细胞疗法是一种很有前景的治疗方法。最近，开发包括病原体特异性T细胞在内的T细胞产品的技术已经成熟，并且现在已按照药品生产质量管理规范（GMP）投入使用。在此，我们旨在总结目前关于针对病毒和霉菌感染的过继性T细胞疗法的知识。
相似文献
1
Immunotherapy for opportunistic infections: Current status and future perspectives.
Virulence. 2016 Nov 16;7(8):939-949. doi: 10.1080/21505594.2016.1207038. Epub 2016 Jul 6.
2
Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options.
Curr Opin Infect Dis. 2017 Aug;30(4):372-376. doi: 10.1097/QCO.0000000000000375.
3
Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.
Curr Hematol Malig Rep. 2020 Apr;15(2):90-102. doi: 10.1007/s11899-020-00557-6.
4
Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation.
Klin Padiatr. 2013 May;225(3):164-9. doi: 10.1055/s-0033-1333749. Epub 2013 May 22.
5
Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation.
Best Pract Res Clin Haematol. 2004 Sep;17(3):479-92. doi: 10.1016/j.beha.2004.06.0054.
6
Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant.
Cytotherapy. 2017 Nov;19(11):1284-1301. doi: 10.1016/j.jcyt.2017.07.012. Epub 2017 Sep 15.
7
Ready-to-use T cells for infection after stem-cell transplant.
Lancet Oncol. 2017 Sep;18(9):e519. doi: 10.1016/S1470-2045(17)30625-3. Epub 2017 Aug 17.
8
Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation.
Cells. 2019 Jan 14;8(1):47. doi: 10.3390/cells8010047.
9
Efficacy and safety of adoptive T-cell therapy in treating cytomegalovirus infections post-haematopoietic stem cell transplantation: A systematic review and meta-analysis.
Rev Med Virol. 2024 Jul;34(4):e2558. doi: 10.1002/rmv.2558.
10
Adoptive immunotherapy with virus-specific T cells.
Best Pract Res Clin Haematol. 2011 Sep;24(3):413-9. doi: 10.1016/j.beha.2011.06.003.
引用本文的文献
1
Use of Specific T Lymphocytes in Treating Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients: A Systematic Review.
Pharmaceutics. 2024 Oct 11;16(10):1321. doi: 10.3390/pharmaceutics16101321.
2
Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy.
Int J Mol Sci. 2019 May 30;20(11):2666. doi: 10.3390/ijms20112666.
3
Robust Identification of Suitable T-Cell Subsets for Personalized CMV-Specific T-Cell Immunotherapy Using CD45RA and CD62L Microbeads.
Int J Mol Sci. 2019 Mar 20;20(6):1415. doi: 10.3390/ijms20061415.
4
Recent Advances in the Treatment of Scedosporiosis and Fusariosis.
J Fungi (Basel). 2018 Jun 18;4(2):73. doi: 10.3390/jof4020073.
5
Infections following allogeneic stem cell transplantation: New concepts, improved insights, and renewed hope for better outcomes.
Virulence. 2016 Nov 16;7(8):898-900. doi: 10.1080/21505594.2016.1252019.
本文引用的文献
1
Optimizing T-cell receptor gene therapy for hematologic malignancies.
Blood. 2016 Jun 30;127(26):3305-11. doi: 10.1182/blood-2015-11-629071. Epub 2016 May 20.
2
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.
3
Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
Rev Med Virol. 2016 May;26(3):161-82. doi: 10.1002/rmv.1873. Epub 2016 Mar 14.
4
Streptamer technology allows accurate and specific detection of CMV-specific HLA-A*02 CD8 T cells by flow cytometry.
Cytometry B Clin Cytom. 2017 Mar;92(2):153-160. doi: 10.1002/cyto.b.21367. Epub 2016 Apr 4.
5
Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-γ Immunomagnetic Selection.
J Immunother. 2016 Jan;39(1):27-35. doi: 10.1097/CJI.0000000000000105.
6
Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study.
Clin Microbiol Infect. 2016 Feb;22(2):179.e1-179.e10. doi: 10.1016/j.cmi.2015.10.017. Epub 2015 Oct 20.
7
T-Cell Responses to EBV.
Curr Top Microbiol Immunol. 2015;391:325-53. doi: 10.1007/978-3-319-22834-1_11.
8
Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge.
Cancer Immunol Immunother. 2015 Jul;64(7):893-902. doi: 10.1007/s00262-015-1710-8. Epub 2015 May 20.
9
Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.
Cytotherapy. 2015 Jul;17(7):989-1007. doi: 10.1016/j.jcyt.2015.03.613. Epub 2015 Apr 9.
10
Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens.
Mycoses. 2015 Jun;58(6):325-36. doi: 10.1111/myc.12318. Epub 2015 Mar 24.
Zotero 插件